NCLifeSci Blog
Stay up to date with the latest from NCLifeSci
Recent Posts
NCBIO stands in solidarity with patient advocates and industry leaders in opposing the Centers for Medicare and Medicaid Services’ draft proposal to restrict coverage for current and future Alzheimer’s drugs targeting beta amyloid, a known hallmark of the disease. Restricting coverage is a bad idea for so many reasons: CMS is competing directly with the…
Read MoreDoes government spending on drug development justify government price controls on medicines? Not when the private sector spends $102 billion on clinical R&D and the NIH spends less than $3 billion.
Read MoreThe ongoing response to the COVID-19 pandemic has highlighted the critical role of the North Carolina life sciences industry in battling our most serious public health threats. When faced with the threat of COVID-19, biotechnology companies – many based right here in North Carolina – answered the call and quickly developed safe and effective vaccines,…
Read MoreA serious approach to addressing climate change must include the proactive elimination of unnecessary paper consumption. Paper is an important and useful material that should be produced and consumed in a responsible and sustainable way, and the existence of digital options that can be utilized safely and effectively should lead to the elimination of outdated…
Read MoreMichelle McMurry-Heath, M.D., Ph.D., president and CEO of the Biotechnology Innovation Organization, released the following statement after the House of Representatives passed the Build Back Better Act on Nov. 19: “The legislation that passed the House today will upend a successful Medicare system and weaken the innovation ecosystem that has made America the leader in…
Read MoreDuring a busy week in Congress, Democrats included a change to the Orphan Drug Tax Credit that would negatively impact research on rare diseases affecting millions of Americans. The U.S. House of Representatives has several committees marking up the Senate’s $3.5 trillion budget reconciliation package. (Here’s BIO’s readout, including news on drug price controls and the…
Read MoreThe summer calm is grinding to a halt as members of Congress have returned to D.C. for what is sure to be a busy legislative sprint that could potentially impact all sectors of the biotech industry.
Read MoreIt’s been a while since we’ve talked about what’s going on at the WTO. Here’s the latest news-and why the proposed waiver of vaccine IP is still a bad idea. The status: The World Trade Organization is still considering a proposal backed by India and South Africa (and supported by the U.S.) to waive the…
Read MoreThe PASTEUR Act, legislation designed to make research and development of new antibiotics economically viable, was reintroduced in Congress last week with bipartisan support. Here’s what it would do and why it matters. Antimicrobial resistance is a big problem. AMR occurs when bacteria, viruses, fungi and parasites no longer respond to antibiotics. If we don’t…
Read MoreLegislation like H.R. 3 that fixes prices for prescription medicines would limit patients’ access to new treatments while doing nothing to lower prices at the pharmacy counter.
Read More